<DOC>
	<DOCNO>NCT01183208</DOCNO>
	<brief_summary>A Phase I , Single-Centre , Double-Blind , Randomised , Placebo-Controlled , Parallel Group , Pharmacokinetic Safety Study Evaluate Systemic Exposure Local Vaginal Exposure Lidocaine Prilocaine Metabolites 2,6 DiMethylAlanine ( 2 , 6 , DMA ) O-Toluidine ; Safety Tolerability PSD502 Female Healthy Volunteer Subjects Following Daily Application Vagina Cervix Seven Days With Three Different Doses PSD502 Placebo</brief_summary>
	<brief_title>A Safety Tolerability Study Administration PSD502</brief_title>
	<detailed_description>The study drug metered-dose anaesthetic spray , develop treatment premature ejaculation ( PE ) . The use anaesthetic topical cream well establish , license topical anaesthetic cream market active ingredient spray ( eutectic mixture local anaesthetic cream 5 % , lidocaine &amp; prilocaine ) . The use cream result concentrate drug direct contact cell , unlike spray . Six clinical study already carry spray ; two involve recruitment 556 PE patient dose 1 year . These study demonstrate prolongation intravaginal ejaculatory latency time safety concern male patient female partner . The partner clinical study participant ask report health change study . Reports vaginal numbness uncommon ; however , effect transfer partner exclude . This study conduct determine effect drug whole body female well local vaginal exposure spray . This study conduct order support marketing application United States ( US ) request U.S. Food Drug Administration .</detailed_description>
	<mesh_term>Premature Ejaculation</mesh_term>
	<mesh_term>EMLA</mesh_term>
	<criteria>Female nonsmoker age 18 year old Willing able provide write informed consent Generally , good health opinion investigator Subject must body mass index 18 30 kg/m2 , inclusive Willing able comply study procedure opinion investigator Negative Papanicolaou smear perform either gynaecological examination screen document 12 month prior study entry Negative drug abuse cotinine test screen Female subject childbearing potential sexually active become sexually active must use method effective contraception 14 day screen continue use end study ( If oral contraceptive use , must stable period 3 month . If barrier method use , latex base polyurethane base ) Female subject postmenopausal must postmenopausal &gt; 1 year confirm elevate serum follicle stimulate hormone screen History significant medical condition would preclude study participation , opinion investigator Currently take , take within 2 week prior screen , concomitant medication could confound interpretation safety pharmacokinetic data PSD502 . Use prescription medication within 14 day overthecounter product within 7 day prior first dose Suffering sexually transmit disease , positive hepatitis B , hepatitis C , human immunodeficiency virus infection Safety testing : abnormality screen , particular liver function test , indicative medical condition would preclude participation , opinion investigator Significant abnormality vaginal mucosa cervix would preclude interpretation examination area could worsen use PSD502 History alcohol drug abuse within 1 year prior screen Known drug sensitivity amidetype local anaesthetic Unlikely understand able comply study procedure , reason , opinion investigator History glucose6phosphate dehydrogenase deficiency use medication would increase susceptibility methemoglobinemia ( e.g. , antimalarial agent ) Use class I ( e.g. , mexiletine , tocainide ) III ( e.g. , amiodarone , sotalol ) antiarrhythmic drug Subject receive investigational ( nonregistered ) drug within 90 day screen Subject physical psychological condition would prevent undertake study procedure , include , limited , follow : Urogynaecological disease recent surgery within 8 week screen would make intravaginal application vaginal examination/colposcopy difficult painful OR Ongoing significant psychiatric disorder ( e.g. , bipolar disease , depression/anxiety disorder schizophrenia ) Subject clinically obvious vaginal infection , active vaginal Candida albicans ( thrush ) , abnormal vaginal discharge Subjects pregnant lactating Subjects menstruate treatment phase Subjects refuse allow primary care physician inform participation Donation blood blood product within 90 day prior dose time study , except require protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>